Balancing QoL Improvement Against Implant Risk: The Phase III Randomized PREPEC Trial Reveals Short- and Long-Term Benefits of Prepectoral Breast Reconstruction

Balancing QoL Improvement Against Implant Risk: The Phase III Randomized PREPEC Trial Reveals Short- and Long-Term Benefits of Prepectoral Breast Reconstruction

At a recent international academic conference, Professor Walter Weber from University Hospital Basel, Switzerland, detailed the results of the international randomized Phase III PREPEC trial (OPBC-02). The study aimed to compare the impact of two implant placement strategies—Prepectoral versus traditional Subpectoral—on the quality of life and safety of patients undergoing implant-based breast reconstruction (IBBR) following therapeutic or prophylactic mastectomy.
Overcoming the Dilemma of First-line TKI Resistance: Olverembatinib Second-line Treatment Achieves 76% CCyR in CP-CML without T315I Mutation

Overcoming the Dilemma of First-line TKI Resistance: Olverembatinib Second-line Treatment Achieves 76% CCyR in CP-CML without T315I Mutation

The treatment of Chronic Myeloid Leukemia (CML) has entered the era of Tyrosine Kinase Inhibitors (TKIs), but the choice of treatment for patients after the failure of first-line therapy remains a focus of clinical attention. Olverembatinib (HQP1351), as the first third-generation TKI independently developed in China, has previously demonstrated excellent efficacy in populations carrying the T315I mutation. However, what is the value of Olverembatinib for patients in the chronic phase (CP-CML) who do not carry the T315I mutation and have developed resistance or intolerance after first-line TKI therapy? At a recent academic conference, Professor Li Weiming from Union Hospital, Tongji Medical College, Huazhong University of Science and Technology shared the latest efficacy and safety data of Olverembatinib in the second-line treatment of CP-CML patients. This article is specially organized for readers.
CGOG 2026 Day 2 | ASCO Neuroendocrine Tumors Highlights Session

CGOG 2026 Day 2 | ASCO Neuroendocrine Tumors Highlights Session

The 2026 Peking University Gastrointestinal Oncology Forum and the 16th CGOG Annual Meeting were held in Beijing from June 9–13, 2026. On June 10, the dedicated ASCO Neuroendocrine Tumors Highlights Session brought together leading Chinese experts to provide in-depth reviews of the latest advances in neuroendocrine tumor (NET) research presented at the 2026 ASCO Annual Meeting.
CGOG 2026 Day 3 | ASCO Highlights Session on Colorectal Cancer

CGOG 2026 Day 3 | ASCO Highlights Session on Colorectal Cancer

On June 11, Day 3 of the 16th Peking University Gastrointestinal Oncology Forum and CGOG Annual Meeting featured the 2026 ASCO Highlights Session on Colorectal Cancer, where leading experts provided in-depth reviews and discussions of the latest advances presented at the 2026 ASCO Annual Meeting. The session was livestreamed across multiple platforms and attracted more than 25,000 online viewers.
Learning from History: Dr. Ludovico Docimo on the Rise of Robotic Surgery in Colorectal ORs

Learning from History: Dr. Ludovico Docimo on the Rise of Robotic Surgery in Colorectal ORs

From May 15 to 17, 2026, the Academic Seminar on Clinical Practices of Colorectal Surgery was held in Hangzhou. Dr. Ludovico Docimo, Professore Ordinario e Primario of the UOC of General, Minimally Invasive and Obesity Surgery at the University of Campania "Luigi Vanvitelli" (Italy), shared his view that robotic surgery will transform colorectal operating rooms, much like laparoscopy did.